|Last Price$279.49||Day Change (%)-1.15%|
|Open Price$284.52||Day Change ($)-3.25|
|Day Range277.52–287.50||52-Week Range154.16–319.83|
As of Mon 12/09/2013 07:08 PM EST | USD
Good day, ladies and gentlemen, and welcome to the Regeneron Pharmaceuticals Third Quarter 2013 Earnings Conference Call. At this time, all participants are in a listen-only mode, later we'll conduct a question-and-answer session and instructions will follow at that time. As a reminder, this ...
Sanofi and Regeneron Report Positive Results with Sarilumab in First Phase 3 Rheumatoid Arthritis Registration Trial
EYLEA® (aflibercept) Injection Approved For The Treatment of Macular Edema Following Central Retinal Vein Occlusion In Japan
Bayer Seeks Japan Approval of VEGF Trap-Eye to Treat Blindness
Regeneron Highlights EYLEA® (aflibercept) Injection Data to Be Presented at American Academy of Ophthalmology Annual Meeting
UPDATE: Macy's, Potbelly gain; Chegg slumps in debut
As part of Aberdeen's acquisition of Artio, some international fund managers to depart. Also, a management change on a T. Rowe Price health-care fund, Columbia hires Putnam's former asset-allocation head, and ClearBridge and Legg Mason Capital Management funds to merge.
Standing out in a good year for stocks.
This trio is worth a closer look.
Brand recognition and product innovation keep the firm's moat wide.